Christin Luft

Christin is
developing technologies that facilitate high-throughput screening
projects. This includes the characterization of reporter gene functions
in various assays related to cancer signaling and autophagy, and the use
of RNAi and CRISPR-mediated gene silencing technologies. Recently,
through an award from the Michael J Fox Foundation, Christin started to
investigate novel drug targets for Parkin-mediated mitophagy in
Parkinsons disease.